Randomized controlled phase II trial of glatiramer acetate in ALS

P. H. Gordon, C. Doorish, J. Montes, R. L. Mosely, B. Diamond, R. B. MacArthur, L. H. Weimer, P. Kaufmann, A. P. Hays, L. P. Rowland, Howard Eliot Gendelman, S. Przedborski, H. Mitsumoto

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

The authors conducted a randomized controlled trial to test the safety and immunology of glatiramer acetate in ALS. Twenty treated patients were randomly assigned to daily or biweekly injections. Ten control patients were selected from another trial and followed up concurrently. Injection reactions were the only common adverse event (p = 0.01). Treated patients showed enhanced lymphocyte proliferation (p = 0.02). The safety profile and immune effects support conducting larger trials of dose selection and efficacy.

Original languageEnglish (US)
Pages (from-to)1117-1119
Number of pages3
JournalNeurology
Volume66
Issue number7
DOIs
StatePublished - Apr 1 2006

Fingerprint

Safety
Injections
Allergy and Immunology
Randomized Controlled Trials
Lymphocytes
Glatiramer Acetate

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Gordon, P. H., Doorish, C., Montes, J., Mosely, R. L., Diamond, B., MacArthur, R. B., ... Mitsumoto, H. (2006). Randomized controlled phase II trial of glatiramer acetate in ALS. Neurology, 66(7), 1117-1119. https://doi.org/10.1212/01.wnl.0000204235.81272.e2

Randomized controlled phase II trial of glatiramer acetate in ALS. / Gordon, P. H.; Doorish, C.; Montes, J.; Mosely, R. L.; Diamond, B.; MacArthur, R. B.; Weimer, L. H.; Kaufmann, P.; Hays, A. P.; Rowland, L. P.; Gendelman, Howard Eliot; Przedborski, S.; Mitsumoto, H.

In: Neurology, Vol. 66, No. 7, 01.04.2006, p. 1117-1119.

Research output: Contribution to journalArticle

Gordon, PH, Doorish, C, Montes, J, Mosely, RL, Diamond, B, MacArthur, RB, Weimer, LH, Kaufmann, P, Hays, AP, Rowland, LP, Gendelman, HE, Przedborski, S & Mitsumoto, H 2006, 'Randomized controlled phase II trial of glatiramer acetate in ALS', Neurology, vol. 66, no. 7, pp. 1117-1119. https://doi.org/10.1212/01.wnl.0000204235.81272.e2
Gordon PH, Doorish C, Montes J, Mosely RL, Diamond B, MacArthur RB et al. Randomized controlled phase II trial of glatiramer acetate in ALS. Neurology. 2006 Apr 1;66(7):1117-1119. https://doi.org/10.1212/01.wnl.0000204235.81272.e2
Gordon, P. H. ; Doorish, C. ; Montes, J. ; Mosely, R. L. ; Diamond, B. ; MacArthur, R. B. ; Weimer, L. H. ; Kaufmann, P. ; Hays, A. P. ; Rowland, L. P. ; Gendelman, Howard Eliot ; Przedborski, S. ; Mitsumoto, H. / Randomized controlled phase II trial of glatiramer acetate in ALS. In: Neurology. 2006 ; Vol. 66, No. 7. pp. 1117-1119.
@article{215e4097a4644bd99479ec6b9a172ea2,
title = "Randomized controlled phase II trial of glatiramer acetate in ALS",
abstract = "The authors conducted a randomized controlled trial to test the safety and immunology of glatiramer acetate in ALS. Twenty treated patients were randomly assigned to daily or biweekly injections. Ten control patients were selected from another trial and followed up concurrently. Injection reactions were the only common adverse event (p = 0.01). Treated patients showed enhanced lymphocyte proliferation (p = 0.02). The safety profile and immune effects support conducting larger trials of dose selection and efficacy.",
author = "Gordon, {P. H.} and C. Doorish and J. Montes and Mosely, {R. L.} and B. Diamond and MacArthur, {R. B.} and Weimer, {L. H.} and P. Kaufmann and Hays, {A. P.} and Rowland, {L. P.} and Gendelman, {Howard Eliot} and S. Przedborski and H. Mitsumoto",
year = "2006",
month = "4",
day = "1",
doi = "10.1212/01.wnl.0000204235.81272.e2",
language = "English (US)",
volume = "66",
pages = "1117--1119",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Randomized controlled phase II trial of glatiramer acetate in ALS

AU - Gordon, P. H.

AU - Doorish, C.

AU - Montes, J.

AU - Mosely, R. L.

AU - Diamond, B.

AU - MacArthur, R. B.

AU - Weimer, L. H.

AU - Kaufmann, P.

AU - Hays, A. P.

AU - Rowland, L. P.

AU - Gendelman, Howard Eliot

AU - Przedborski, S.

AU - Mitsumoto, H.

PY - 2006/4/1

Y1 - 2006/4/1

N2 - The authors conducted a randomized controlled trial to test the safety and immunology of glatiramer acetate in ALS. Twenty treated patients were randomly assigned to daily or biweekly injections. Ten control patients were selected from another trial and followed up concurrently. Injection reactions were the only common adverse event (p = 0.01). Treated patients showed enhanced lymphocyte proliferation (p = 0.02). The safety profile and immune effects support conducting larger trials of dose selection and efficacy.

AB - The authors conducted a randomized controlled trial to test the safety and immunology of glatiramer acetate in ALS. Twenty treated patients were randomly assigned to daily or biweekly injections. Ten control patients were selected from another trial and followed up concurrently. Injection reactions were the only common adverse event (p = 0.01). Treated patients showed enhanced lymphocyte proliferation (p = 0.02). The safety profile and immune effects support conducting larger trials of dose selection and efficacy.

UR - http://www.scopus.com/inward/record.url?scp=33646087896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646087896&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000204235.81272.e2

DO - 10.1212/01.wnl.0000204235.81272.e2

M3 - Article

C2 - 16606934

AN - SCOPUS:33646087896

VL - 66

SP - 1117

EP - 1119

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 7

ER -